Table 1.
Cell-cycle phase of transfected SAOS-2 cells
| Transfection | % cells in phase
|
||
|---|---|---|---|
| G1 | S | G2/M | |
| Exp. 1 | |||
| CMV | 43.8 | 32.9 | 23.3 |
| B-MYB | 48.3 | 30.8 | 20.9 |
| Cyclin A | 43.9 | 35.3 | 20.8 |
| B-MYB + cyclin A | 29.9 | 52.5 | 17.6 |
| B-MYB + cyclin A | 29.9 | 59.5 | 10.6 |
| Exp. 2 | |||
| CMV | 39.0 | 27.7 | 33.3 |
| B-MYB | 28.1 | 34.9 | 37.0 |
| B-MYB | 35.5 | 28.2 | 36.3 |
| Cyclin A | 33.9 | 29.0 | 37.0 |
| Cyclin A | 30.9 | 27.9 | 41.1 |
| B-MYB + cyclin A | 19.2 | 44.4 | 36.5 |
| B-MYB + cyclin A | 16.7 | 46.1 | 37.2 |
| Exp. 3 | |||
| CMV | 30.2 | 37.5 | 32.3 |
| B-MYB | 31.5 | 40.5 | 28.0 |
| Cyclin E | 22.0 | 37.9 | 40.2 |
| B-MYB + cyclin E | 24.5 | 41.6 | 34.0 |
| B-MYB + cyclin E | 21.3 | 45.6 | 33.1 |
| Exp. 4 | |||
| CMV | 40.8 | 39.9 | 19.3 |
| B-MYB | 41.2 | 32.7 | 26.1 |
| B-MYB | 34.5 | 34.0 | 31.5 |
| Cyclin E | 18.2 | 48.4 | 33.4 |
| Cyclin E | 19.9 | 47.8 | 32.3 |
| B-MYB + cyclin E | 19.4 | 57.6 | 23.0 |
| B-MYB + cyclin E | 16.3 | 59.0 | 24.7 |
| Exp. 5 | |||
| CMV | 30.7 | 35.6 | 33.7 |
| B-MYB | 30.4 | 35.3 | 34.3 |
| Cyclin B1 | 31.4 | 36.0 | 32.5 |
| Cyclin B1 | 34.1 | 31.3 | 34.6 |
| B-MYB + cyclin B1 | 26.0 | 36.0 | 37.4 |
| B-MYB + cyclin B1 | 26.0 | 35.6 | 38.4 |
Data are expressed as the percentage of the FITC-anti-CD20-stained cells in the various phases of the cell cycle. Various independent transfection experiments were performed on separate days. We preferred to present the entire set of data, rather than the averages with standard deviations, because variations in the efficiency of transfection and staining, in separate experiments, may cause large fluctuations, so that a statistical analysis would not add significance to the raw data.